Frontlight ResearchEarly access
TerminatedPhase 3
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
Key facts
- Who runs it
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
- Where
- Spain12 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 14 people enrolled
- Started
- 10 Jul 2024
- Ended
- 6 Oct 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Metoprolol Injection
- saline 0.9%
- Record updated
- 2 June 2026
- Why it stopped
- Persistently low recruitment of subjects
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Patients (≥18 years and <80 years) with a clinical diagnosis of ARDS of any aetiology (pneumonia, including SARS-CoV-2, sepsis, pancreatitis, bronchospasm and trauma) admitted to the ICU
- Orotracheal intubation (OTI) and mechanical ventilation within 72 hours prior to randomisation
- Moderate-severe ARDS (PaO2/FiO2: ≤200 mmHg under standardised conditions (PEEP≥5 cm H2O)
- Heart rate ≥ 60 bpm
- Invasive systolic blood pressure ≥ 110 mmHg
Who cannot take part
- Prolonged hospital admission prior to randomisation (i.e. ≥7 days at the time of randomisation)
- Concomitant acute heart failure (cardiac index ≤2.5 L/m2 or pulmonary capillary pressure ≥15 mmHg or clinical suspicion)
- Concomitant pulmonary embolism
- Known asthma before admission (with active bronchodilator therapy)
- Active beta-blocker treatment prior to admission (i.e. within 3 months prior to admission)
- Life expectancy due to other processes (cancer, degenerative diseases, etc.) of less than 6 months
- Second-degree atrioventricular (AV) block, 2:1 AV block, high-grade/advanced AV block and third-degree AV block. Also significant sinus bradycardia, which would be implied by having a heart rate >60 bpm as an inclusion criterion
- Known severe peripheral arterial disease
- Reduced left ventricular ejection fraction (LVEF <50%)
- Right ventricular (RV) systolic dysfunction
- Pregnant or breastfeeding women
- Cardiogenic shock
- Persistent invasive blood pressure <110 mmHg despite vasopressor agents
- Use of noradrenaline at concentrations greater than 0.2 µg/kg/min at the time of the randomisation
- Use of dobutamine within 48 hours before randomisation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Respiratory Distress Syndrome (ARDS).
The 2 groups in the trial
- MetoprololExisting treatment, for comparison
Participants will be administered IV Metoprolol tartrate 15 mg (3 ampoules of 5 ml) diluted in 100 ml of saline.
Treatment: Metoprolol Injection
- SalinePlacebo, for comparison
Participants will be administered IV saline (0.9% sodium chloride) (3 ampoules of 5 ml) diluted in 100 ml of saline.
Treatment: saline 0.9%
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the to Assess the Efficacy of Intravenous Metoprolol in Patients With Acute Respiratory Distress Syndrome (ARDS).
- Record updated
- 2 June 2026